Therillume is a clinical-stage neuro-oncology therapeutics company bringing precision medicine to patients with Glioblastoma (GBM) and Neurofibromatosis Types 1 and 2 (NF1 and NF2). Therillume is a human therapeutic company, spinning out from Recombinetics Inc., and leveraging its pioneering precise gene-editing platform and intellectual property to identify, validate and expedite high-quality candidates through clinical development.